Litcius/Paper detail

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial

Frederick J. Raal, Vimal Mehta, Meral Kayıkçıoğlu, Dirk Blom, Preeti Gupta, Avishay Elis, Traci Turner, Christopher B. Daniels, Jeffrey Vest, Tracy Mitchell, Kate Caldwell, El Mustapha Bahassi, David Kallend, Evan A. Stein

2025The Lancet Diabetes & Endocrinology23 citationsDOI

Topics & Concepts

EvolocumabMedicinePCSK9AlirocumabOpen labelCrossover studyCrossoverPhase (matter)Internal medicineRandomized controlled trialPlaceboCholesterolAlternative medicineApolipoprotein BLDL receptorLipoproteinPathologyArtificial intelligenceApolipoprotein A1Computer scienceChemistryOrganic chemistryLipoproteins and Cardiovascular HealthReceptor Mechanisms and SignalingCholesterol and Lipid Metabolism
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial | Litcius